Bayer To Pay Isis Immediate $100 Mln Up-front Payment - Quick Facts

(RTTNews) - Isis Pharmaceuticals, Inc. (ISIS) announced that its license agreement with Bayer HealthCare to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Based on the approval, Bayer will pay Isis an immediate $100 million up-front payment.

In total, Isis is eligible to receive up to $375 million in payments, including the upfront payment and a $55 million near-term milestone payment upon advancement of the program following the Phase 2 study in patients with compromised kidney function. Isis is also eligible to receive tiered royalties in the low to high twenty percent range on gross margins of ISIS-FXIRx.